Prescott Group Capital Management L.L.C. raised its holdings in Emergent Biosolutions Inc. (NYSE:EBS – Free Report) by 48.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,143,481 shares of the biopharmaceutical company’s stock after purchasing an additional 370,710 shares during the quarter. Prescott Group Capital Management L.L.C.’s holdings in Emergent Biosolutions were worth $7,547,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $39,525,000. Dimensional Fund Advisors LP increased its position in shares of Emergent Biosolutions by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after purchasing an additional 504,553 shares during the last quarter. Ancora Advisors LLC acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth about $8,949,000. Renaissance Technologies LLC increased its position in shares of Emergent Biosolutions by 13.7% during the 1st quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock worth $5,445,000 after purchasing an additional 78,900 shares during the last quarter. Finally, Palisade Capital Management LP purchased a new stake in Emergent Biosolutions in the 2nd quarter valued at about $4,316,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.
Emergent Biosolutions Stock Down 3.0%
Shares of NYSE EBS opened at $6.24 on Wednesday. Emergent Biosolutions Inc. has a twelve month low of $4.36 and a twelve month high of $14.06. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. The stock has a fifty day simple moving average of $6.52 and a 200-day simple moving average of $7.99.
Emergent Biosolutions (NYSE:EBS – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Emergent Biosolutions had a negative return on equity of 0.40% and a negative net margin of 40.16%. The firm had revenue of $110.00 million for the quarter, compared to the consensus estimate of $123.22 million. As a group, sell-side analysts expect that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They issued an “underweight” rating on the stock. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Finally, Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.00.
View Our Latest Stock Report on EBS
Key Stories Impacting Emergent Biosolutions
Here are the key news stories impacting Emergent Biosolutions this week:
- Positive Sentiment: Third-quarter adjusted loss per share was $0.36, narrower than the $0.39 loss analysts expected. The company also said quarterly revenue of $110 million was in line with its own guidance. Earnings report
- Positive Sentiment: Restructuring actions are expected to produce $40 million in annualized savings, which could support profitability as the company continues its transformation. Long-term investor takeaways
- Neutral Sentiment: Trading in EBS was temporarily halted for an LULD pause. The notice gives no specific catalyst or directional signal, but indicates a period of elevated price volatility.
- Negative Sentiment: Emergent cut its FY 2026 revenue outlook to $600 million–$645 million, below the $656.2 million consensus estimate. Coverage characterized this as a second consecutive cut to revenue and EBITDA guidance, raising concerns about the company’s near-term growth and execution. Guidance coverage
- Negative Sentiment: Despite the adjusted EPS beat, quarterly revenue of $110 million fell short of analysts’ $123.22 million estimate, tempering the earnings surprise. Third-quarter results
Insiders Place Their Bets
In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of Emergent Biosolutions stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total value of $126,202.00. Following the completion of the transaction, the director directly owned 111,921 shares of the company’s stock, valued at $793,519.89. The trade was a 13.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.
Emergent Biosolutions Profile
Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.
The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.
Featured Articles
- Five stocks we like better than Emergent Biosolutions
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS – Free Report).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
